{"id":52392,"date":"2021-07-30T10:33:00","date_gmt":"2021-07-30T10:33:00","guid":{"rendered":"https:\/\/www.verificat.cat\/abdala-works\/"},"modified":"2021-07-30T10:33:00","modified_gmt":"2021-07-30T10:33:00","slug":"abdala-works","status":"publish","type":"post","link":"https:\/\/www.verificat.cat\/en\/abdala-works\/","title":{"rendered":"Abdala"},"content":{"rendered":"<p><br \/>\n<\/p>\n<p>The <a href=\"https:\/\/www.cigb.edu.cu\/\" target=\"_blank\" rel=\"noopener\">Center for Genetic Engineering and Biotechnology<\/a> (CIGB) in Cuba has developed the first approved vaccine of the country under the name CIGB-66 or Abdala. It is about a formula of <a href=\"https:\/\/www.verificat.cat\/infografia\/tipus-de-vacunes\" target=\"_blank\" rel=\"noopener\">protein subunits<\/a>, composed by <a href=\"https:\/\/vacunasaep.org\/profesionales\/noticias\/covid-19-vacunas-investigadas-en-cuba\" target=\"_blank\" rel=\"noopener\">a synhtetic fractions of the S protein<\/a> from SARS-CoV-2 named RBD. By recognising that this protein should not be present, the body creates T-lymphocytes and antibodies that will remember how to fight the virus that causes covid-19 if we are infected in the future.<\/p>\n<p>The Cuban injection has passed <a href=\"https:\/\/rpcec.sld.cu\/en\/trials\/RPCEC00000346-En\" target=\"_blank\" rel=\"noopener\">phase I\/II<\/a> and <a href=\"https:\/\/rpcec.sld.cu\/trials\/RPCEC00000359-En\" target=\"_blank\" rel=\"noopener\">III<\/a> clinical trials according to its manufacturers. The first phase involved 132 volunteers to assess the safety of the vaccine in healthy patients aged 19-54 years, and a second phase of <a href=\"https:\/\/www.bmj.com\/content\/372\/bmj.n309\/rr-0\" target=\"_blank\" rel=\"noopener\">760 patients<\/a> aged 19-80 years, which may include some with comorbidities or chronic diseases.<\/p>\n<p>The third phase of clinical trials involved a total of <a href=\"https:\/\/www.presidencia.gob.cu\/es\/noticias\/abdala-es-un-candidato-vacunal-muy-seguro\/\" target=\"_blank\" rel=\"noopener\">48,290 volunteers<\/a>, according to Cuban government information, among whom <a href=\"https:\/\/www.cigb.edu.cu\/product\/abdala-cigb-66\/\" target=\"_blank\" rel=\"noopener\">the efficacy of the drug<\/a> the efficacy of the drug was estimated at <a href=\"https:\/\/twitter.com\/DiazCanelB\/status\/1407121738790494208\" target=\"_blank\" rel=\"noopener\">2,27%<\/a> against symptomatic infection, and 100% against more severe disease or death, although the results have not yet been published in any scientific article. The formulation <a href=\"https:\/\/www.cecmed.cu\/covid-19\/aprobaciones\" target=\"_blank\" rel=\"noopener\">was approved for emergency use<\/a> in Cuba in July 2021.<\/p>\n<p>In May, in parallel with the development of the last phase of clinical trials, and before getting the authorisation, the Cuban Government initiated <a href=\"https:\/\/salud.msp.gob.cu\/comenzo-satisfactoriamente-intervencion-sanitaria-en-grupos-de-riesgo-y-territorios-del-pais\/\" target=\"_blank\" rel=\"noopener\">the inoculation of the vaccine<\/a> at a large scale with both Abdala and the other Cuban candidate, Soberana 02, before they were officially authorised. The Cuban Ministry of Health estimates that <a href=\"https:\/\/salud.msp.gob.cu\/actualizacion-de-la-vacunacion-en-el-marco-de-los-estudios-de-los-candidatos-vacunales-cubanos-y-la-intervencion-sanitaria\/\" target=\"_blank\" rel=\"noopener\">more than 8 million<\/a> doses will be distributed during this campaign.<\/p>\n<p>The Cuban vaccine is administered in three doses, each of them separated 14 days from the previous one. The Cigb has also informed that it is preserved between 2 and 8 &ordm;C.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Center for Genetic Engineering and Biotechnology (CIGB) in Cuba  [&#8230;]<\/p>\n","protected":false},"author":15,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[169],"tags":[208],"class_list":["post-52392","post","type-post","status-publish","format-standard","hentry","category-uncategorized","tag-vaccines-en","vc-legacy-post"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.verificat.cat\/en\/wp-json\/wp\/v2\/posts\/52392","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.verificat.cat\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.verificat.cat\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.verificat.cat\/en\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/www.verificat.cat\/en\/wp-json\/wp\/v2\/comments?post=52392"}],"version-history":[{"count":0,"href":"https:\/\/www.verificat.cat\/en\/wp-json\/wp\/v2\/posts\/52392\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.verificat.cat\/en\/wp-json\/wp\/v2\/media?parent=52392"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.verificat.cat\/en\/wp-json\/wp\/v2\/categories?post=52392"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.verificat.cat\/en\/wp-json\/wp\/v2\/tags?post=52392"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}